WallStSmart

Alumis Inc (ALMS)vsBeiGene, Ltd. (ONC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BeiGene, Ltd. generates 22116% more annual revenue ($5.34B vs $24.05M). ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).

ALMS

Avoid

24

out of 100

Grade: F

Growth: 4.3Profit: 2.5Value: 5.0Quality: 7.5
Piotroski: 6/9Altman Z: -4.23

ONC

Hold

42

out of 100

Grade: D

Growth: 8.0Profit: 5.0Value: 3.0Quality: 6.5
Piotroski: 5/9Altman Z: 0.26
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ALMS.

ONCSignificantly Overvalued (-1983.5%)

Margin of Safety

-1983.5%

Fair Value

$16.86

Current Price

$283.45

$266.59 premium

UndervaluedFair: $16.86Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALMS1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.1010/10

Conservative balance sheet, low leverage

ONC2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
32.8%10/10

Revenue surging 32.8% year-over-year

Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

ALMS4 concerns · Avg: 3.8/10
Price/BookValuation
8.0x4/10

Trading at 8.0x book value

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

ONC4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
7.5%3/10

ROE of 7.5% — below average capital efficiency

Profit MarginProfitability
5.4%3/10

5.4% margin — thin

P/E RatioValuation
111.0x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : ALMS

The strongest argument for ALMS centers on Debt/Equity.

Bull Case : ONC

The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.

Bear Case : ALMS

The primary concerns for ALMS are Price/Book, Revenue Growth, EPS Growth.

Bear Case : ONC

The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.

Key Dynamics to Monitor

ALMS profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.

ONC is growing revenue faster at 32.8% — sustainability is the question.

ONC generates stronger free cash flow (131M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ONC scores higher overall (42/100 vs 24/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alumis Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Alumis Inc. (ALMS) is an innovative leader in the development and commercialization of high-performance aluminum products, serving critical sectors such as automotive, aerospace, and construction. The company harnesses proprietary technologies to advance material science while adhering to sustainable manufacturing practices, ensuring minimal environmental impact. Focused on research and development, Alumis is strategically positioned to capitalize on emerging market opportunities and expand its diverse product portfolio. With a commitment to operational excellence and stakeholder value, Alumis aims to sustain long-term growth through continuous innovation.

Visit Website →

BeiGene, Ltd.

HEALTHCARE · BIOTECHNOLOGY · USA

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.

Visit Website →

Want to dig deeper into these stocks?